Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors.
Saved in:
| Title: | Phase II study of magrolimab combined with docetaxel in previously treated metastatic advanced solid tumors. |
|---|---|
| Authors: | Italiano A; Département d'oncologie médicale - Sarcomes, Centre Régional de Lutte Contre le Cancer (CLCC) Institut Bergonié, Bordeaux, France., García Manrique T; Department of Medical Oncology, Hospital Universitario Virgen Macarena, Seville, Spain., Grande Pulido E; Servicio de Oncología Médica, MD Anderson Cancer Center, Madrid, Spain., Kerrigan K; Division of Medical Oncology, Huntsman Cancer Institute, University of Utah School of Medicine, Salt Lake City, UT, United States., Fléchon A; Department of Medical Oncology, Centre Léon Bérard Centre Régional de Lutte Contre le Cancer, Lyon, France., Martínez Pérez J; Medical Oncology Department, Hospital Universitario Virgen del Rocío, Seville, Spain., Żurawski B; Department of Outpatient Chemotherapy, Centrum Onkologii Szpital im. prof. Franciszka Łukaszczyka w Bydgoszczy, Bydgoszcz, Poland., Furqan M; Department of Internal Medicine, Holden Comprehensive Cancer Center, University of Iowa Hospitals and Clinics, Iowa City, IA, United States., Juan-Vidal O; Medical Oncology Service, Hospital Universitari i Politècnic la Fe, Valencia, Spain., Vaishampayan U; Division of Hematology/Oncology, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, United States., Fares C; Department of Medical Oncology, Virginia Piper Cancer Center, Allina Health Cancer Institute, Minneapolis, MN, United States., Fang B; Department of Medical Oncology, Astera Cancer Care, East Brunswick, NJ, United States., Vicuna B; Department of Medical Oncology, Comprehensive Cancer Centers of Nevada, Las Vegas, NV, United States., Greillier L; Multidisciplinary Oncology and Therapeutic Innovations Department, Centre d'Essais Précoces en Cancérologie de Marseille (CEPCM), Assistance Publique-Hôpitaux de Marseille (AP-HM), Marseille, France., Subbiah V; Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, University of Texas MD Anderson Cancer Center, Houston, TX, United States., Dong M; Gilead Sciences, Inc., Foster City, CA, United States., Song K; Gilead Sciences, Inc., Foster City, CA, United States., Zhang Y; Gilead Sciences, Inc., Foster City, CA, United States., Kim Y; Gilead Sciences, Inc., Foster City, CA, United States., Paz-Ares L; Department of Medical Oncology, Hospital Universitario 12 de Octubre, H12O-CNIO Lung Cancer Unit, Complutense University and Ciberonc, Madrid, Spain. |
| Source: | Frontiers in oncology [Front Oncol] 2026 Apr 22; Vol. 16, pp. 1786385. Date of Electronic Publication: 2026 Apr 22 (Print Publication: 2026). |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
Be the first to leave a comment!
